These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 36869784)

  • 21. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial.
    Vranckx P; Valgimigli M; Jüni P; Hamm C; Steg PG; Heg D; van Es GA; McFadden EP; Onuma Y; van Meijeren C; Chichareon P; Benit E; Möllmann H; Janssens L; Ferrario M; Moschovitis A; Zurakowski A; Dominici M; Van Geuns RJ; Huber K; Slagboom T; Serruys PW; Windecker S;
    Lancet; 2018 Sep; 392(10151):940-949. PubMed ID: 30166073
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectiveness and safety of P2Y12 inhibitors in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention: a nationwide registry-based study.
    Godtfredsen SJ; Kragholm KH; Leutscher P; Jørgensen SH; Christensen MK; Butt JH; Gislason G; Køber L; Fosbøl EL; Sessa M; Bhatt DL; Torp-Pedersen C; Pareek M
    Eur Heart J Acute Cardiovasc Care; 2022 Sep; 11(9):697-705. PubMed ID: 35950769
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of new oral or intravenous P2Y12 inhibitors and clopidogrel on major ischemic and bleeding events in patients with coronary artery disease: a meta-analysis of randomized trials.
    Tang XF; Fan JY; Meng J; Jin C; Yuan JQ; Yang YJ
    Atherosclerosis; 2014 Apr; 233(2):568-578. PubMed ID: 24534451
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUS-TIMI 54.
    Dellborg M; Bonaca MP; Storey RF; Steg PG; Im KA; Cohen M; Bhatt DL; Oude Ophuis T; Budaj A; Hamm C; Spinar J; Kiss RG; Lopez-Sendon J; Kamensky G; Van de Werf F; Ardissino D; Kontny F; Montalescot G; Johanson P; Bengtsson O; Himmelmann A; Braunwald E; Sabatine MS
    Eur Heart J Cardiovasc Pharmacother; 2019 Oct; 5(4):200-206. PubMed ID: 31218354
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In-hospital outcomes of ticagrelor versus clopidogrel in patients 75 years or older with acute coronary syndrome: findings from the Improving Care for Cardiovascular Disease in China (CCC)-Acute Coronary Syndrome Project.
    Yang N; Liu J; Liu J; Hao Y; Smith JSC; Huo Y; Fonarow GC; Ge J; Morgan L; Ma C; Han Y; Zhao D;
    Age Ageing; 2022 Nov; 51(11):. PubMed ID: 36413586
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Secondary prevention of antithrombotic therapy in patients with stable cardiovascular disease at high ischemic risk: A network meta-analysis of randomized controlled trials.
    Zhu H; Xu X; Wang H; Chen Q; Fang X; Zheng J; Gao B; Tong G; Zhou L; Chen T; Huang J
    Front Cardiovasc Med; 2022; 9():1040473. PubMed ID: 36698936
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of P2Y12 Inhibitors in Acute Coronary Syndromes in the Australian Population.
    Hou M; Hyun K; Chew DP; Kritharides L; Amos D; Brieger D
    Heart Lung Circ; 2022 Aug; 31(8):1085-1092. PubMed ID: 35589483
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk of Major Bleeding With Potent Antiplatelet Agents After an Acute Coronary Event: A Comparison of Ticagrelor and Clopidogrel in 5116 Consecutive Patients in Clinical Practice.
    Mullen L; Meah MN; Elamin A; Aggarwal S; Shahzad A; Shaw M; Hasara J; Rashid M; Fisher M; Ali T; Patel B; Ding WY; Grainger R; Heseltine T; Kirmani BH; Obeidat M; Kasolo Y; Thatchil J; Khand A
    J Am Heart Assoc; 2021 Apr; 10(8):e019467. PubMed ID: 33834845
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of clopidogrel and potent P2Y 12 -inhibitors on mortality and stroke in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: a systematic review and meta-analysis.
    Aradi D; Komócsi A; Vorobcsuk A; Serebruany VL
    Thromb Haemost; 2013 Jan; 109(1):93-101. PubMed ID: 23197191
    [TBL] [Abstract][Full Text] [Related]  

  • 30. P2Y12 Inhibitors Plus Aspirin Versus Aspirin Alone in Patients With Minor Stroke or High-Risk Transient Ischemic Attack.
    Li ZX; Xiong Y; Gu HQ; Fisher M; Xian Y; Johnston SC; Wang YJ
    Stroke; 2021 Jul; 52(7):2250-2257. PubMed ID: 34039032
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of long-term ticagrelor monotherapy following 1-month dual antiplatelet therapy in patients who underwent complex percutaneous coronary intervention: insights from the Global Leaders trial.
    Serruys PW; Takahashi K; Chichareon P; Kogame N; Tomaniak M; Modolo R; Chang CC; Komiyama H; Soliman O; Wykrzykowska JJ; de Winter RJ; Ferrario M; Dominici M; Buszman P; Bolognese L; Tumscitz C; Benit E; Stoll HP; Hamm C; Steg PG; Onuma Y; Jüni P; Windecker S; Vranckx P; Colombo A; Valgimigli M
    Eur Heart J; 2019 Aug; 40(31):2595-2604. PubMed ID: 31397487
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antithrombotic Therapy in Patients With Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or With Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial.
    Windecker S; Lopes RD; Massaro T; Jones-Burton C; Granger CB; Aronson R; Heizer G; Goodman SG; Darius H; Jones WS; Aschermann M; Brieger D; Cura F; Engstrøm T; Fridrich V; Halvorsen S; Huber K; Kang HJ; Leiva-Pons JL; Lewis BS; Malaga G; Meneveau N; Merkely B; Milicic D; Morais J; Potpara TS; Raev D; Sabaté M; de Waha-Thiele S; Welsh RC; Xavier D; Mehran R; Alexander JH;
    Circulation; 2019 Dec; 140(23):1921-1932. PubMed ID: 31557056
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of Different Chronic Maintenance Antithrombotic Strategies in Patients with Coronary Artery Disease: A Systematic Review and Network Meta-Analysis.
    Zhang J; Chen Z; Cai Y; Li C; He Y
    Cardiovasc Ther; 2023; 2023():5446271. PubMed ID: 37636560
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Meta-Analysis Comparing P2Y
    Baldetti L; Melillo F; Moroni F; Gallone G; Pagnesi M; Venuti A; Beneduce A; Calvo F; Gramegna M; Godino C; D'Ascenzo F; De Ferrari GM; Capodanno D; Cappelletti AM
    Am J Cardiol; 2020 Jun; 125(12):1815-1822. PubMed ID: 32305225
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Features of antiplatelet therapy with P2Y12 receptor inhibitors in patients with myocardial infarction according to the Russian Register of Acute Myocardial Infarction REGION-MI.
    Boytsov SA; Shakhnovich RM; Tereschenko SN; Erlikh AD; Kukava NG; Pevsner DV; Rytova YK
    Kardiologiia; 2022 Sep; 62(9):44-53. PubMed ID: 36206137
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oral Antiplatelet Therapy After Acute Coronary Syndrome: A Review.
    Kamran H; Jneid H; Kayani WT; Virani SS; Levine GN; Nambi V; Khalid U
    JAMA; 2021 Apr; 325(15):1545-1555. PubMed ID: 33877270
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomized trial to compare the safety of rivaroxaban vs aspirin in addition to either clopidogrel or ticagrelor in acute coronary syndrome: The design of the GEMINI-ACS-1 phase II study.
    Povsic TJ; Roe MT; Ohman EM; Steg PG; James S; Plotnikov A; Mundl H; Welsh R; Bode C; Gibson CM
    Am Heart J; 2016 Apr; 174():120-8. PubMed ID: 26995378
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and Safety of Ticagrelor Monotherapy by Clinical Presentation: Pre-Specified Analysis of the GLOBAL LEADERS Trial.
    Vranckx P; Valgimigli M; Odutayo A; Serruys PW; Hamm C; Steg PG; Heg D; Mc Fadden EP; Onuma Y; Benit E; Janssens L; Diletti R; Ferrario M; Huber K; Räber L; Windecker S; Jüni P;
    J Am Heart Assoc; 2021 Sep; 10(18):e015560. PubMed ID: 34533034
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ticagrelor as compared to conventional antiplatelet agents in coronary artery disease: A comprehensive meta-analysis of 15 randomized trials.
    Verdoia M; Savonitto S; Dudek D; Kedhi E; De Luca G
    Vascul Pharmacol; 2021 Apr; 137():106828. PubMed ID: 33385541
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pooled Analysis of Bleeding, Major Adverse Cardiovascular Events, and All-Cause Mortality in Clinical Trials of Time-Constrained Dual-Antiplatelet Therapy After Percutaneous Coronary Intervention.
    McClure JD; Ramsay JC; Berry C
    J Am Heart Assoc; 2020 Aug; 9(16):e017109. PubMed ID: 32779497
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.